Zobrazeno 1 - 7
of 7
pro vyhledávání: '"MARTINA SPISAROVA"'
Autor:
Martina Spisarova, Stanislav Losse, Petr Jakubec, Igor Hartmann, Milan Kral, Jiri Ehrmann, Marek Szkorupa, Hana Studentova, Bohuslav Melichar
Publikováno v:
Biomedical Papers, Vol 168, Iss 2, Pp 181-186 (2024)
Objective. Intravesical administration of bacillus Calmette-Guérin is standard adjuvant treatment of non-muscle invasive bladder cancer. In spite of the fact that this immunotherapy is locoregional, there are still risk of some complications. Method
Externí odkaz:
https://doaj.org/article/e8be09d6c72a490da4ffd65b4f686f55
Autor:
Hana Studentova, Jindriska Volakova, Martina Spisarova, Anezka Zemankova, Kvetoslava Aiglova, Tomas Szotkowski, Bohuslav Melichar
Publikováno v:
BMC Gastroenterology, Vol 22, Iss 1, Pp 1-10 (2022)
Abstract Background Sunitinib and pazopanib are both oral small molecule multityrosine kinase inhibitors (MTKI) used in the treatment of renal cell carcinoma (RCC). Hepatotoxicity or “liver injury” is the most important adverse effect of pazopani
Externí odkaz:
https://doaj.org/article/0d1fca5cc18a4a52b0ed320697e74d14
Autor:
Radmila Lemstrova, Dominika Flasarova, Martina Spisarova, Bohuslav Melichar, Martin Lovecek, Roman Havlik, Cestmir Neoral, Beatrice Mohelnikova-Duchonova, Dusan Klos
Publikováno v:
Biomedical Papers, Vol 164, Iss 3, Pp 300-306 (2020)
Background: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is a treatment modality for peritoneal surface malignancies with efficacy reported in many trials. Discrepancies, however, in the indication criteria, the e
Externí odkaz:
https://doaj.org/article/70d092901d3545c298cae96c81e9e1ed
Autor:
Hana Studentova, Anezka Zemankova, Martina Spisarova, Daniela Skanderova, Zbynek Tudos, Bohuslav Melichar, Vladimir Student
Publikováno v:
Medicina, Vol 58, Iss 3, p 336 (2022)
Background and Objectives: Complete pathological response after ipilimumab and nivolumab combination therapy in a patient with intermediate prognosis renal cell carcinoma is an uncommon finding. Case presentation: A 60-year-old man presented with syn
Externí odkaz:
https://doaj.org/article/eb6298dc37554341b4125173da4b9c27
Autor:
MARTINA SPISAROVA, BOHUSLAV MELICHAR, JARMILA JURANOVA, ANEZKA ZEMANKOVA, TOMAS ADAM, KATERINA MATOUSOVA, LENKA JAVORSKA, LENKA KUJOVSKA KRCMOVA, DOROTA TURONOVA, HANA STUDENTOVA
Publikováno v:
In Vivo
Background/Aim: Biomarkers that would identify patients unlikely to respond to immunotherapy with immune checkpoint inhibitors (ICIs) remain an unmet medical need. Patients and Methods: In the present study, we have retrospectively evaluated the asso
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bcad4b93551a3d314f352d860b75ae98
https://europepmc.org/articles/PMC9843774/
https://europepmc.org/articles/PMC9843774/
Autor:
Martina Spisarova, Stanislav Losse, Petr Jakubec, Igor Hartmann, Milan Kral, Jiri Ehrmann, Marek Szkorupa, Hana Studentova, Bohuslav Melichar
Publikováno v:
Biomedical Papers.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fe25df9914b6eb1cda48c478d11cb57a
https://doi.org/10.5507/bp.2022.051
https://doi.org/10.5507/bp.2022.051
Administration of Nivolumab in Metastatic Renal Cell Cancer Following Treatment With mTOR Inhibitors
Autor:
Jindrich, Kopecky, Ondrej, Kubecek, Tomas, Buchler, Bohuslav, Melichar, Alexandr, Poprach, Milada, Zemanova, Jana, Katolicka, Igor, Kiss, Jaroslav, Hajek, Hana, Studentova, Martina, Spisarova
Publikováno v:
In Vivo
Background/Aim: Immunotherapy with checkpoint inhibitors is currently considered a cornerstone of metastatic renal clear cell cancer (mRCC) therapy. Despite the general improvement in the survival of patients with mRCC, there are some clinical situat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::4a5118b0b3730c9b9dd1e0f4a65b9d0a
https://pubmed.ncbi.nlm.nih.gov/34410998
https://pubmed.ncbi.nlm.nih.gov/34410998